Sendai virus-based production of HIV type 1 subtype B and subtype E envelope glycoprotein 120 antigens and their use for highly sensitive detection of subtype-specific serum antibodies

AIDS Research and Human Retroviruses

Volumn 15, Issue 12, 1999, Pages 1109-1120

  Toriyoshi, Hidenobu ^a   Shioda, Tatsuo ^b   Sato, Hironori ^a   Sakaguchi, Masahiro ^a   Eda, Yasuyuki ^c   Tokiyoshi, Sachio ^c   Kato, Kayoko ^a   Nohtomi, Kyoko ^a   Kusagawa, Shigeru ^a   Taniguchi, Kiyomi ^a   Shiino, Teiichiro ^a   Kato, Atsushi ^b   Foongladda, Suporn ^d   Linkanonsakul, Sirirat ^e   Oka, Shin Ichi ^f   Iwamoto, Aikichi ^b   Wasi, Chantapong ^d   Nagai, Yoshiyuki ^a,b   Takebe, Yutaka ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Chemo Sero Therapeutic Research Institute   (Japan)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Bamrasnaradura Infectious Disease Institute   (Thailand)

^f NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT PROTEIN; VIRUS VECTOR;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME IMMUNOASSAY; GLYCOPROTEIN SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; SENDAI VIRUS; VALIDATION PROCESS; VIRUS STRAIN;

ANTIBODIES, VIRAL; BASE SEQUENCE; BLOTTING, WESTERN; CLONING, MOLECULAR; DNA PRIMERS; FLOW CYTOMETRY; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOENZYME TECHNIQUES; RECOMBINANT PROTEINS; RESPIROVIRUS; SENSITIVITY AND SPECIFICITY;

EID: 0033543091     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310403     Document Type: Article

References (51)

1. Dalgleish AG, Beverley PC, Clapham PR, et al.: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (London) 1984;312:763-767.
2. Klatzmann D, Champagne E, Chamaret S, et al.: T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (London) 1984;312:767-768.
3. Alkhatib G, Combadiere C, Broder CC, et al.: CC CKR5: A RANTES, MIP-1 alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958.
4. Deng H, Liu R, Ellmeier W, et al: Identification of a major coreceptor for primary isolates of HIV-1. Nature (London) 1996; 381:661-666.
5. Dragic T, Litwin V, Allaway GP, et al: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (London) 1996;381:667-673.
6. Feng Y, Broder CC, Kennedy PE, et al: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
7. Cheng-Mayer C, Seto D, Tateno M, et al: Biologic features of HIV-1 that correlate with virulence in the host. Science 1988; 240:80-82.
8. Fenyö EM, Morfeldt-Manson L, Chiodi F, et al: Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988;62:4414-4419.
9. Robey WG, Arthur LO, Matthews TJ, et al: Prospect for prevention of human immunodeficiency virus infection: Purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci USA 1986;83:7023-7027.
10. Myers G, Korber B, Foley B, et al : Human Retroviruses and AIDS 1996. Los Alamos National Laboratory, Los Alamos, New Mexico, 1996.
11. Simon F, Mauclere P, Roques P, et al : Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nature Med 1998;4:1032-1037.
12. Cheingsong-Popov R, Osmanov S, Pau CP, et al.: Serotyping of HIV type 1 infections: Definition, relationship to viral genetic sub-types, and assay evaluation. UNAIDS Network for HIV-1 Isolation and Characterization. AIDS Res Hum Retroviruses 1998; 14:311-318.
13. Esparza J, Osmanov S, Kallings LO, et al: Planning for HIV vaccine trials: The World Health Organization perspective. AIDS 1991;5(Suppl. 2):S159-163.
14. Ou CY, Takebe Y, Weniger BG, et al: Independent introduction two major HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet 1993;341:1171-1174.
15. Nerurkar VR, Nguyen HT, Dashwood WM, et al.: HIV type 1 sub-type E in commercial sex workers and injection drug users in southern Vietnam. AIDS Res Hum Retroviruses 1996;12:841-843.
16. Weniger BG, Takebe Y, Ou CY, et al: The molecular epidemiology of HIV in Asia. AIDS 1994;8(Suppl. 2):S13-28.
17. Kato A, Sakai Y, Shioda T, et al.: Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells 1996;1:569-579.
18. Gershoni IM, Lapidot M, Zakai N, et al.: Protein blot analysis of virus receptors: Identification and characterization of the Sendai virus receptor. Biochim Biophys Acta 1986;856:19-26.
19. Markwell MA, Svennerholm L, and Paulson JC: Specific ganglio-sides function as host cell receptors for Sendai virus. Proc Natl Acad Sci USA 1981;78:5406-5410.
20. Scheid A, Hsu M, and Choppin PW: Role of paramyxovirus glycoproteins in the interactions between viral and cell membranes. Soc Gen Physiol Ser 1980;34:119-130.
21. Markwell MA, Portner A, and Schwartz AL: An alternative route of infection for viruses: Entry by means of the asialoglycoprotein receptor of a Sendai virus mutant lacking its attachment protein. Proc Natl Acad Sci 1985;28:978-982.
22. Yu D, Shioda T, Kato A, et al.: Sendai virus-based expression of HIV-1 gp120: Reinforcement by the V(-) version. Genes Cells 1997;2:457-466.
23. Moriya C, Shioda T, Tashiro K, et al.: Large quantity production with extreme convenience of human SDF-1α and SDF-1β by a Sendai virus vector. FEBS Lett 1998;425:105-111.
24. Kato A, Kiyotani K, Sakai Y, et al.: The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J 1997;16:578-587.
25. Hasan MK, Kato A, Shioda T, et al.: Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3′ proximal first locus. J Gen Virol 1997;78:2813-2820.
26. Kato A, Kiyotani K, Sakai Y, et al.: Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis. J Virol 1997;71:7266-7272.
27. Sato H, Taniguchi K, Tomita Y, et al.: Evidence for the selective pressure to reduce heterogeneity of HIV-1 subtype E envelope V3-loop sequences in an intrafamilial infection case. AIDS 1997;11: 396-397.
28. Calain P and Roux L: The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 1993;67:4822-4830.
29. Adachi A, Gendelman HE, Koenig S, et al.: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59:284-291.
30. Pau CP, Lee-Thomas S, Auwanit W, et al.: Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand. AIDS 1993;7:337-340.
31. Kusagawa S, Sato H, Watanabe, et al.: Genetic and serologic characterization of HIV-1 prevailing in Myanmar (Burma). AIDS Res Hum Retroviruses 1998;14:1379-1385.
32. Komiyama N, Hattori N, Inoue J, et al.: Nucleotide sequences of gag and env genes of a Japanese isolate of HIV-1 and their expression in bacteria. AIDS Res Hum Retroviruses 1989;5:411-419.
33. Hattori T, Shiozaki K, Eda Y, et al.: Characteristics of the principal neutralizing determinant of HIV-1 prevalent in Japan. AIDS Res Hum Retroviruses 1991;7:825-830.
34. Shimizu N, Takeuchi Y, Naruse T, et al.: Six strains of human immunodeficiency virus type 1 isolated in Japan and their molecular phytogeny. J Mol Evol 1992;35:329-336.
35. Matsushita S, Robert-Guroff M, Rusche J, et al.: Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol 1988; 62:2107-2114.
36. Okamoto Y, Eda Y, Ogura A, et al.: In SCID-hu mice, passive transfer of a humanized antibody prevents infection and atrophic change of medulla in human thymic implant due to intravenous inoculation of primary HIV-1 isolate. J Immunol 1998;160:69-76.
37. Engleman EG, Benike CJ, Glickman E, et al: Antibodies to membrane structures that distinguish suppressor/cytotoxic and helper T lymphocyte subpopulations block the mixed leukocyte reaction in man. J Exp Med 1981;154:193-198.
38. Ichimura H, Kliks SC, Visrutaratna S, et al.: Biological, serological, and genetic characterization of HIV-1 subtype E isolates from northern Thailand. AIDS Res Hum Retroviruses 1994;10:263-269.
39. Benkirane M, Him M, Carriere D, et al.: Functional epitope analysis of the human CD4 molecule: antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3-like region of CD4. J Virol 1995;69:6898-6903.
40. Mascola JR, Louder MK, Surman SR, et al.: Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 1996;12:1319-1328.
41. Thompson SD and Portner A: Localization of functional sites on the hemagglutinin-neuraminidase glycoprotein of Sendai virus by sequence analysis of antigenic and temperature-sensitive mutants. Virology 1987;160:1-8.
42. Thompson SD, Laver WG, Murti KG, et al.: Isolation of a biologically active soluble form of the hemagglutinin-neuraminidase protein of Sendai virus. J Virol 1988;62:4653-4660.
43. Back NK, Smit L, De Jong JJ, et al.: An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 1994;199:431-438.
44. Benjouad A, Mabrouk K, Gluckman JC, et al.: Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein. FEBS Lett 1994;341:244-250.
45. Montefiori DC, Stewart K, Ahearn JM, et al.: Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). J Virol 1993;67:2699-2706.
46. VanCott TC, Mascola JR, Kaminski RW, et al.: Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol 1997;71:4319-4330.
47. Moore JP, Cao Y, Leu J, et al.: Inter-and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gpl20 antigenic serotypes. J Virol 1996;70:427-444.
48. Gorny MK, Mascola JR, Israel ZR, et al.: A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. AIDS Res Hum Retroviruses 1998;14:213-221.
49. Louisirirotchanakul S, Beddows S, Cheingsong-Popov R, et al.: Characterization of sera from subjects infected with HIV-1 sub-types B and E in Thailand by antibody binding and neutralization. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:315-320.
50. Weber J, Fenyö EM, Beddows S, et al.: Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol 1996;70:7827-7832.
51. Kostrikis LG, Cao Y, Ngai H, et al.: Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from sub-types A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996; 70:445-45.